ARTICLE | Emerging Company Profile
Biometheus: Placebo parity
Biometheus' genetic marker to identify placebo responders could shrink trials
June 30, 2014 7:00 AM UTC
Biometheus LLC has a biomarker for a polymorphism that can prospectively identify patients who will respond to placebo in clinical trials. The marker could allow companies to exclude these patients up front and cut trial sizes in half.
Last week, Biometheus emerged from stealth mode and announced an exclusive option to IP from Beth Israel Deaconess Medical Center that covers a marker for a polymorphism in the catechol-O-methyl-transferase (COMT) gene...